Download Files:
Products Details
Product Description
– Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM). Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis[1][2].
Web ID
– HY-A0037
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C28H31NO2
Citations
– NPJ Breast Cancer. 2022 Dec 14;8(1):130.|Gynecol Oncol. 2019 Jul;154(1):199-206.|Mol Cancer Ther. 2020 Jul;19(7):1395-1405.
References
– [1]Lainé M, et al. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 May 12. 23(1):54. |[2]Andreano KJ, et al. The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Mol Cancer Ther. 2020 Jul. 19(7):1395-1405. |[3]Andersson A, et al. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford). 2016 Mar;55(3):553-63.
CAS Number
– 180916-16-9
Molecular Weight
– 413.55
SMILES
– OC1=CC=C2[C@@H](C3=CC=C(OCCN4CCCC4)C=C3)[C@@H](C5=CC=CC=C5)CCC2=C1
Clinical Information
– Launched
Research Area
– Cancer; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Estrogen Receptor/ERR
Pathway
– Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
